Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

VKVeronika KapustováLBLucie BroskevičováTPTereza Popková

Discussion

Loading...

Member takes

Overview

Analysis finds reduced NK cell effector phenotypes and highlights treatment efficacy challenges in patients with multiple myeloma.

Key Points

  • Progression-free survival was significantly worse with higher proportions of CD38+ NK cells in treated multiple myeloma patients.
  • Use of daratumumab correlated with a median progression-free survival of 37 months in relapsed/refractory multiple myeloma.
  • Studies revealed the treatment led to significant depletion of CD38+ NK and T cell populations post-therapy.
  • Results indicate a complex interplay of immune cells, emphasizing the need for strategies addressing treatment resistance.

Cite This Study

Kapustová et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6d5https://doi.org/10.1182/blood-2025-5720
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell immune landscape associated with isatuximab, carfilzomib, lenalidomide, and dexamethasone induction efficacy in newly diagnosed myeloma2025 · 1 citations
  2. 2Immune population dynamics predict multiple myeloma progression while on daratumumab maintenance therapy following autologous stem cell transplant2025
  3. 3Integrative genomic, single-cell, and functional profiling uncovers immune consequences of the CD48–CD244 axis in NK cells in multiple myeloma2025
  4. 4Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)2025
  5. 5Novel indirubin-3-monoxime derivative I3MV-8b enhances anti-CD38 monoclonal antibody efficacy in multiple myeloma through dual proteasome and HDAC6 inhibition2025